Compounds > methotrexate
Page last updated: 2024-08-25

methotrexate and Glycogen Storage Disease Type II

methotrexate has been researched along with Glycogen Storage Disease Type II in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (20.00)29.6817
2010's8 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bronsema, KJ; Hoogeveen-Westerveld, M; Kroos-de Haan, MA; Pijnappel, WWMP; Poelman, E; van de Merbel, NC; van den Hout, JMP; van der Ploeg, AT1
Abdul-Rahman, O; Desai, AK; Feigenbaum, A; Gupta, N; Joseph, AM; Kazi, ZB; Kishnani, PS; Kronn, D; McVie-Wylie, A; Nampoothiri, S; Niyazov, DM; Packman, S; Richards, S; Rizzo, WB; Sabbadini, M; Scherer, K; Segel, R; Sherry, L; Sung, C; Tanpaiboon, P; Troxler, RB1
Biamino, E; Mongini, T; Pagliardini, V; Porta, F; Ricci, F; Spada, M1
De Groot, AS; Desai, AK; Kazi, ZB; Kishnani, PS; Martin, RF; Martin, WD; Terry, FE1
Bali, DS; Banugaria, SG; Chakraborty, P; Charrow, J; Dearmey, SM; Harmatz, P; Kishnani, PS; Labarthe, F; Milleson, C; Patel, TT; Prater, SN; Raiman, JA; Rehder, CW; Rosenberg, AS; Sheets, KB; Wang, RA1
Ivkosic, IE; Kovacevic, T; Kuzmanic-Samija, R; Markic, J; Mestrovic, J; Metlicic, V; Polic, B; Stricevic, L1
Pipkin, W; Riojas, C1
Bailey, C; Banugaria, SG; Conway, RL; Feldman, JD; Gera, R; Kishnani, PS; Kobori, JA; McGann, JK; Prater, SN; Rosenberg, AS; Tannenbaum, JA; Viskochil, D1
Garman, R; Housman, M; Joseph, A; Munroe, K; Richards, S1
Arvanitopoulos, E; Chen, A; Donnabella, V; Martiniuk, F; Plotz, P; Raben, N; Rom, WN; Slonim, AE1

Trials

1 trial(s) available for methotrexate and Glycogen Storage Disease Type II

ArticleYear
High Sustained Antibody Titers in Patients with Classic Infantile Pompe Disease Following Immunomodulation at Start of Enzyme Replacement Therapy.
    The Journal of pediatrics, 2018, Volume: 195

    Topics: alpha-Glucosidases; Antibodies; B-Lymphocytes; Biomarkers; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Replacement Therapy; Female; Follow-Up Studies; Glycogen Storage Disease Type II; Humans; Immunoglobulins, Intravenous; Immunomodulation; Immunosuppressive Agents; Infant; Male; Methotrexate; Rituximab; Treatment Outcome

2018

Other Studies

9 other study(ies) available for methotrexate and Glycogen Storage Disease Type II

ArticleYear
An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease.
    Genetics in medicine : official journal of the American College of Medical Genetics, 2019, Volume: 21, Issue:4

    Topics: Age of Onset; alpha-Glucosidases; Cross Reactions; Enzyme Replacement Therapy; Female; Glycogen Storage Disease Type II; Humans; Immune Tolerance; Infant; Infant, Newborn; Male; Methotrexate

2019
Early higher dosage of alglucosidase alpha in classic Pompe disease.
    Journal of pediatric endocrinology & metabolism : JPEM, 2018, Dec-19, Volume: 31, Issue:12

    Topics: alpha-Glucosidases; Enzyme Replacement Therapy; Female; Glycogen Storage Disease Type II; Humans; Immunologic Factors; Infant; Infant, Newborn; Male; Methotrexate; Prognosis; Rituximab; Treatment Outcome

2018
HLA- and genotype-based risk assessment model to identify infantile onset pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA).
    Clinical immunology (Orlando, Fla.), 2019, Volume: 200

    Topics: alpha-Glucosidases; Antibodies; Computer Simulation; Cross Reactions; Enzyme Replacement Therapy; Epitope Mapping; Epitopes, T-Lymphocyte; Glycogen Storage Disease Type II; HLA-DRB1 Chains; Humans; Immune Tolerance; Immunoglobulins, Intravenous; Immunologic Factors; Infant; Methotrexate; Recombinant Proteins; Risk Assessment; Rituximab

2019
Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT.
    PloS one, 2013, Volume: 8, Issue:6

    Topics: Algorithms; Antibodies, Monoclonal, Murine-Derived; Clinical Laboratory Techniques; Cross Reactions; Early Diagnosis; Enzyme Replacement Therapy; Female; Glycogen Storage Disease Type II; Humans; Immunoglobulins; Immunosuppression Therapy; Infant; Infant, Newborn; Male; Methotrexate; Rituximab; Safety; Time Factors; Treatment Outcome

2013
Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: a 3-year follow-up study.
    Wiener klinische Wochenschrift, 2014, Volume: 126, Issue:3-4

    Topics: Antibodies, Monoclonal, Murine-Derived; Croatia; Drug Therapy, Combination; Female; Follow-Up Studies; gamma-Globulins; Glycogen Storage Disease Type II; Humans; Immunologic Factors; Immunosuppressive Agents; Infant; Injections, Intravenous; Methotrexate; Rituximab; Treatment Outcome

2014
Initiation of ECMO for ventilator-dependent respiratory failure in an infant with Pompe's.
    Pediatric surgery international, 2014, Volume: 30, Issue:5

    Topics: Enzyme Replacement Therapy; Extracorporeal Membrane Oxygenation; Follow-Up Studies; Glycogen Storage Disease Type II; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Infant; Male; Methotrexate; Respiratory Insufficiency; Treatment Outcome; Ventilator-Induced Lung Injury

2014
Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease.
    Genetics in medicine : official journal of the American College of Medical Genetics, 2013, Volume: 15, Issue:2

    Topics: Antibodies; Antineoplastic Agents; Boronic Acids; Bortezomib; Child; Child, Preschool; Drug Therapy, Combination; Glycogen Storage Disease Type II; Humans; Immunoglobulins, Intravenous; Male; Methotrexate; Plasma Cells; Pyrazines; Treatment Outcome

2013
Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model.
    Clinical and experimental immunology, 2008, Volume: 152, Issue:1

    Topics: alpha-Glucosidases; Animals; Disease Models, Animal; Dose-Response Relationship, Immunologic; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Glycogen Storage Disease Type II; Immune Tolerance; Immunoglobulin G; Immunosuppressive Agents; Injections, Intraperitoneal; Injections, Intravenous; Male; Methotrexate; Mice; Mice, Knockout; Recombinant Proteins

2008
Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line.
    Biochemical and biophysical research communications, 2000, Oct-05, Volume: 276, Issue:3

    Topics: alpha-Glucosidases; Animals; Blotting, Southern; CHO Cells; Cricetinae; Fibroblasts; Gene Deletion; Gene Dosage; Glucan 1,4-alpha-Glucosidase; Glycogen Storage Disease Type II; Humans; Immunoelectrophoresis; Lymphocytes; Mannosephosphates; Methotrexate; Mice; Mice, Knockout; Monocytes; Motor Activity; Phenotype; Recombinant Proteins; RNA, Messenger; Tetrahydrofolate Dehydrogenase

2000